Hypertrophic cardiomyopathy epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Soroush}} | {{CMG}}; {{AE}} {{Soroush}} | ||
==Overview== | ==Overview== | ||
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. Prevalence rates has been reported between 1:500 (0.2%) and 1:3,000 (0.03%) because variations in study designs and cohort characteristics including different age groups and ethnicity. According to the the CARDIA (Coronary Artery Risk Development in Young Adults) cohort study that used standard echocardiography in 4,111 unrelated people 23 to 35 years of age, HCM prevalence is reported as 1 in 500 persons (0.2%). Nevertheless lower prevalence has been reported in some European countries such as Germany (0.07%). A recent analysis of U.S. claims data reported a prevalence of clinically diagnosed HCM in approximately 1:3,000 (0.03%) | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
| Line 8: | Line 9: | ||
*The incidence/prevalence of Hypertrophic cardiomyopathy is approximately [number range] per 100,000 individuals worldwide. | *The incidence/prevalence of Hypertrophic cardiomyopathy is approximately [number range] per 100,000 individuals worldwide. | ||
*In [year], the incidence/prevalence of Hypertrophic cardiomyopathy was estimated to be [number range] cases per 100,000 individuals worldwide. | *In [year], the incidence/prevalence of Hypertrophic cardiomyopathy was estimated to be [number range] cases per 100,000 individuals worldwide. | ||
<ref name="pmid29723226">{{cite journal| author=Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J et al.| title=Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. | journal=PLoS One | year= 2018 | volume= 13 | issue= 5 | pages= e0196612 | pmid=29723226 | doi=10.1371/journal.pone.0196612 | pmc=5933727 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29723226 }} </ref> | <ref name="pmid29723226">{{cite journal| author=Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J et al.| title=Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. | journal=PLoS One | year= 2018 | volume= 13 | issue= 5 | pages= e0196612 | pmid=29723226 | doi=10.1371/journal.pone.0196612 | pmc=5933727 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29723226 }} </ref> | ||
===Prevalence=== | ===Prevalence=== | ||
| Line 24: | Line 26: | ||
*[Chronic disease name] is usually first diagnosed among [age group]. | *[Chronic disease name] is usually first diagnosed among [age group]. | ||
*[Acute disease name] commonly affects [age group]. | *[Acute disease name] commonly affects [age group]. | ||
Prevalence increased with advancing age and showed a constant yearly rise. | |||
===Race=== | ===Race=== | ||
*There is no racial predilection to Hypertrophic cardiomyopathy. | *There is no racial predilection to Hypertrophic cardiomyopathy. | ||
*Hypertrophic cardiomyopathy usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop Hypertrophic cardiomyopathy. | *Hypertrophic cardiomyopathy usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop Hypertrophic cardiomyopathy. | ||
prevalence of clinically diagnosed HCM in Germany is lower than in systematic population studies based on echocardiographic diagnosis. | |||
===Gender=== | ===Gender=== | ||
*Hypertrophic cardiomyopathy affects men and women equally. | *Hypertrophic cardiomyopathy affects men and women equally. | ||
Revision as of 01:16, 12 December 2019
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy epidemiology and demographics On the Web |
|
FDA on Hypertrophic cardiomyopathy epidemiology and demographics |
|
CDC on Hypertrophic cardiomyopathy epidemiology and demographics |
|
Hypertrophic cardiomyopathy epidemiology and demographics in the news |
|
Blogs on Hypertrophic cardiomyopathy epidemiology and demographics |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. Prevalence rates has been reported between 1:500 (0.2%) and 1:3,000 (0.03%) because variations in study designs and cohort characteristics including different age groups and ethnicity. According to the the CARDIA (Coronary Artery Risk Development in Young Adults) cohort study that used standard echocardiography in 4,111 unrelated people 23 to 35 years of age, HCM prevalence is reported as 1 in 500 persons (0.2%). Nevertheless lower prevalence has been reported in some European countries such as Germany (0.07%). A recent analysis of U.S. claims data reported a prevalence of clinically diagnosed HCM in approximately 1:3,000 (0.03%)
Epidemiology and Demographics
Incidence
- The incidence/prevalence of Hypertrophic cardiomyopathy is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of Hypertrophic cardiomyopathy was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of Hypertrophic cardiomyopathy is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of Hypertrophic cardiomyopathy was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of Hypertrophic cardiomyopathy is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of Hypertrophic cardiomyopathy is approximately [number range].
Age
- Patients of all age groups may develop Hypertrophic cardiomyopathy.
- The incidence of Hypertrophic cardiomyopathy increases with age; the median age at diagnosis is [#] years.
- Hypertrophic cardiomyopathy commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Prevalence increased with advancing age and showed a constant yearly rise.
Race
- There is no racial predilection to Hypertrophic cardiomyopathy.
- Hypertrophic cardiomyopathy usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop Hypertrophic cardiomyopathy.
prevalence of clinically diagnosed HCM in Germany is lower than in systematic population studies based on echocardiographic diagnosis.
Gender
- Hypertrophic cardiomyopathy affects men and women equally.
- [Gender 1] are more commonly affected by Hypertrophic cardiomyopathy than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of Hypertrophic cardiomyopathy cases are reported in [geographical region].
- Hypertrophic cardiomyopathy is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J; et al. (2018). "Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients". PLoS One. 13 (5): e0196612. doi:10.1371/journal.pone.0196612. PMC 5933727. PMID 29723226.